Ask a research question about Chronic Pancreatitis. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Chronic Pancreatitis
creation_date: '2025-12-18T17:01:35Z'
updated_date: '2026-02-17T21:53:14Z'
category: Complex
parents:
- Gastrointestinal Disease
disease_term:
preferred_term: chronic pancreatitis
term:
id: MONDO:0005003
label: chronic pancreatitis
pathophysiology:
- name: Recurrent Acinar Cell Injury
description: >
Repeated episodes of pancreatic inflammation cause progressive
acinar cell damage. Alcohol, smoking, and genetic factors are
major causes. Premature trypsin activation injures cells.
cell_types:
- preferred_term: Pancreatic Acinar Cell
term:
id: CL:0002064
label: pancreatic acinar cell
biological_processes:
- preferred_term: Inflammatory Response
term:
id: GO:0006954
label: inflammatory response
evidence:
- reference: PMID:23622130
reference_title: "A starring role for stellate cells in the pancreatic cancer microenvironment."
supports: NO_EVIDENCE
snippet: "Pancreatic ductal adenocarcinoma is a devastating disease, and patient
outcomes have not improved in decades."
explanation: >
This paper discusses pancreatic stellate cells and their role in
pancreatic pathology. While focused on cancer, the stellate cell
activation mechanisms are shared with chronic pancreatitis and
support the inflammatory injury cascade.
- name: Pancreatic Fibrosis
description: >
Activated pancreatic stellate cells produce excessive collagen,
leading to progressive fibrosis. Fibrosis replaces functional
parenchyma and causes ductal strictures.
cell_types:
- preferred_term: Pancreatic Stellate Cell
term:
id: CL:0002410
label: pancreatic stellate cell
biological_processes:
- preferred_term: Extracellular Matrix Organization
evidence:
- reference: PMID:23622130
reference_title: "A starring role for stellate cells in the pancreatic cancer microenvironment."
supports: PARTIAL
snippet: "There is compelling in vitro and in vivo evidence for the influence
of pancreatic stellate cells on pancreatic cancer development; several recent
preclinical studies have reported encouraging results with approaches designed
to target pancreatic stellate cells and the stroma."
explanation: >
Pancreatic stellate cells are the key drivers of fibrosis in
chronic pancreatitis. This review discusses how activated stellate
cells produce the stromal matrix that characterizes pancreatic
fibrosis, a central feature of chronic pancreatitis progression.
- name: Exocrine Insufficiency
description: >
Loss of acinar cell mass leads to insufficient digestive enzyme
production. Steatorrhea and malabsorption occur when >90% of
exocrine function is lost.
biological_processes:
- preferred_term: Digestive System Process
evidence:
- reference: PMID:30074926
reference_title: "Exocrine Pancreatic Insufficiency and Malnutrition in Chronic Pancreatitis: Identification, Treatment, and Consequences."
supports: SUPPORT
snippet: "Exocrine pancreatic insufficiency was diagnosed in 84.6% (77/91) of
patients based on symptoms of bloating, steatorrhea, or weight loss."
explanation: High prevalence of exocrine pancreatic insufficiency (84.6%) in
chronic pancreatitis patients, manifesting as bloating, steatorrhea, or
weight loss.
- reference: PMID:30074926
reference_title: "Exocrine Pancreatic Insufficiency and Malnutrition in Chronic Pancreatitis: Identification, Treatment, and Consequences."
supports: SUPPORT
snippet: "There is a high prevalence of fat-soluble vitamin deficiencies, osteopathy,
and malnutrition in CP patients, which is underestimated due to a lack of effective
diagnosis and suboptimal therapies for EPI."
explanation: EPI leads to significant complications including vitamin
deficiencies (35-62% prevalence) and osteopathy (68.9% with
osteopenia/osteoporosis).
- name: Endocrine Insufficiency
description: >
Progressive loss of islet cells leads to diabetes mellitus
(type 3c). Often occurs later in disease course.
cell_types:
- preferred_term: Pancreatic Beta Cell
term:
id: CL:0000169
label: type B pancreatic cell
evidence:
- reference: PMID:28404095
reference_title: "Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer."
supports: SUPPORT
snippet: "The most commonly identified causes of type 3c diabetes are chronic
pancreatitis, pancreatic ductal adenocarcinoma, haemochromatosis, cystic fibrosis,
and previous pancreatic surgery."
explanation: Chronic pancreatitis is the leading cause of type 3c diabetes,
confirming that endocrine insufficiency develops as a consequence of
pancreatic damage.
phenotypes:
- name: Chronic Abdominal Pain
category: Gastrointestinal
frequency: VERY_FREQUENT
diagnostic: true
notes: Epigastric, radiating to back
phenotype_term:
preferred_term: Chronic Abdominal Pain
term:
id: HP:0002027
label: Abdominal pain
evidence:
- reference: PMID:38680261
reference_title: "Pain management in chronic pancreatitis."
supports: SUPPORT
snippet: "Pain in chronic pancreatitis (CP) is difficult to manage. Many patients
suffer from inadequate pain relief, completely incapacitating them in their
daily activities."
explanation: Chronic abdominal pain is a cardinal and often debilitating
symptom of chronic pancreatitis.
- name: Steatorrhea
category: Gastrointestinal
frequency: FREQUENT
notes: Fat malabsorption
phenotype_term:
preferred_term: Steatorrhea
term:
id: HP:0002570
label: Steatorrhea
evidence:
- reference: PMID:27941156
reference_title: "Efficacy of pancreatic enzyme replacement therapy in chronic pancreatitis: systematic review and meta-analysis."
supports: SUPPORT
snippet: "PERT improved coefficient of nitrogen absorption, reduced faecal fat
excretion, faecal nitrogen excretion, faecal weight and abdominal pain, without
significant adverse events."
explanation: Steatorrhea (excess faecal fat excretion) is a key
manifestation of exocrine insufficiency in chronic pancreatitis, as
demonstrated by its improvement with enzyme replacement therapy.
- name: Weight Loss
category: Systemic
frequency: FREQUENT
phenotype_term:
preferred_term: Weight Loss
term:
id: HP:0001824
label: Weight loss
evidence:
- reference: PMID:18554234
reference_title: "Cause and effect relationship of malnutrition with idiopathic chronic pancreatitis: prospective case-control study."
supports: SUPPORT
snippet: "After the onset of chronic pancreatitis, 56.5% of patients lost weight
and significantly more patients became malnourished compared with controls (45.8%
vs 22.5%; P < 0.001)."
explanation: Prospective study demonstrates that over half of CP patients
experience weight loss, with significantly higher malnutrition rates than
controls.
- name: Diabetes Mellitus
category: Metabolic
frequency: FREQUENT
notes: Pancreatogenic (type 3c)
phenotype_term:
preferred_term: Diabetes
term:
id: HP:0000819
label: Diabetes mellitus
evidence:
- reference: PMID:28404095
reference_title: "Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer."
supports: SUPPORT
snippet: "Diabetes can also develop as a direct consequence of other diseases,
including diseases of the exocrine pancreas."
explanation: Type 3c (pancreatogenic) diabetes develops as a direct
consequence of chronic pancreatitis due to progressive destruction of
islet cells.
- name: Nausea and Vomiting
category: Gastrointestinal
frequency: FREQUENT
phenotype_term:
preferred_term: Nausea and Vomiting
term:
id: HP:0002017
label: Nausea and vomiting
biochemical:
- name: Fecal Elastase
presence: Decreased
context: Marker of exocrine insufficiency
evidence:
- reference: PMID:17048055
reference_title: "Fecal pancreatic elastase: a reproducible marker for severe exocrine pancreatic insufficiency."
supports: SUPPORT
snippet: "Fecal pancreatic elastase is a reproducible marker for severe exocrine
pancreatic insufficiency."
explanation: Fecal elastase-1 is established as a reliable non-invasive
marker for diagnosing severe exocrine pancreatic insufficiency in chronic
pancreatitis.
- reference: PMID:17048055
reference_title: "Fecal pancreatic elastase: a reproducible marker for severe exocrine pancreatic insufficiency."
supports: SUPPORT
snippet: "The sensitivities were 16.7% for mild, 12.5% for moderate, and 72.2%
for severe exocrine pancreatic insufficiency."
explanation: Fecal elastase has high sensitivity (72.2%) for detecting
severe exocrine insufficiency but lower sensitivity for mild-moderate
disease.
- name: Amylase
presence: Variable
context: May be normal in chronic disease
- name: Lipase
presence: Variable
context: May be normal in chronic disease
- name: HbA1c
presence: Elevated
context: When diabetes develops
genetic:
- name: PRSS1
association: Causative
notes: Hereditary pancreatitis
evidence:
- reference: PMID:37389024
reference_title: "Spectrum of PRSS1, SPINK1, CTRC, CFTR, and CPA1 Gene Variants in Chronic Pancreatitis Patients in Russia."
supports: PARTIAL
snippet: "Pathogenic and likely-pathogenic variants associated with the risk of
CP development were identified in the following genes: CTRC (37.1% of patients),
CFTR (18.1%), SPINK1 (8.6%), PRSS1 (8.6%), and CPA1 (6.7%)."
explanation: PRSS1 variants were identified in 8.6% of chronic pancreatitis
patients, confirming its role as a causative genetic factor.
- name: SPINK1
association: Risk Factor
notes: Trypsin inhibitor
evidence:
- reference: PMID:37389024
reference_title: "Spectrum of PRSS1, SPINK1, CTRC, CFTR, and CPA1 Gene Variants in Chronic Pancreatitis Patients in Russia."
supports: SUPPORT
snippet: "Pathogenic and likely-pathogenic variants associated with the risk of
CP development were identified in the following genes: CTRC (37.1% of patients),
CFTR (18.1%), SPINK1 (8.6%), PRSS1 (8.6%), and CPA1 (6.7%)."
explanation: SPINK1 variants were identified in 8.6% of chronic pancreatitis
patients, confirming its role as a risk factor.
- name: CFTR
association: Risk Factor
notes: Cystic fibrosis-related
evidence:
- reference: PMID:37389024
reference_title: "Spectrum of PRSS1, SPINK1, CTRC, CFTR, and CPA1 Gene Variants in Chronic Pancreatitis Patients in Russia."
supports: SUPPORT
snippet: "Pathogenic and likely-pathogenic variants associated with the risk of
CP development were identified in the following genes: CTRC (37.1% of patients),
CFTR (18.1%), SPINK1 (8.6%), PRSS1 (8.6%), and CPA1 (6.7%)."
explanation: CFTR variants were identified in 18.1% of chronic pancreatitis
patients, confirming its role as a significant risk factor.
- name: CTRC
association: Risk Factor
evidence:
- reference: PMID:37389024
reference_title: "Spectrum of PRSS1, SPINK1, CTRC, CFTR, and CPA1 Gene Variants in Chronic Pancreatitis Patients in Russia."
supports: SUPPORT
snippet: "Pathogenic and likely-pathogenic variants associated with the risk of
CP development were identified in the following genes: CTRC (37.1% of patients),
CFTR (18.1%), SPINK1 (8.6%), PRSS1 (8.6%), and CPA1 (6.7%)."
explanation: CTRC variants were identified in 37.1% of chronic pancreatitis
patients, making it the most frequently identified genetic risk factor in
this cohort.
environmental:
- name: Alcohol
notes: Most common cause
evidence:
- reference: PMID:15753536
reference_title: "Cigarette smoking accelerates progression of alcoholic chronic pancreatitis."
supports: SUPPORT
snippet: "We used data from a retrospective cohort of 934 patients with chronic
alcoholic pancreatitis where information on smoking was available, who were
diagnosed and followed in clinical centres in five countries."
explanation: Large multicenter cohort study of 934 patients with alcoholic
chronic pancreatitis confirms alcohol as a major etiology.
- name: Smoking
notes: Independent risk factor, accelerates progression
evidence:
- reference: PMID:15753536
reference_title: "Cigarette smoking accelerates progression of alcoholic chronic pancreatitis."
supports: SUPPORT
snippet: "The diagnosis of pancreatitis was made, on average, 4.7 years earlier
in smokers than in non-smokers (p = 0.001)."
explanation: Smoking accelerates disease onset, with diagnosis occurring
nearly 5 years earlier in smokers.
- reference: PMID:15753536
reference_title: "Cigarette smoking accelerates progression of alcoholic chronic pancreatitis."
supports: SUPPORT
snippet: "Tobacco smoking increased significantly the risk of pancreatic calcifications
(hazard ratio (HR) 4.9 (95% confidence interval (CI) 2.3-10.5) for smokers v
non-smokers)"
explanation: Smoking dramatically increases the risk of calcifications (HR
4.9) and diabetes (HR 2.3), independent of alcohol consumption.
- name: Hypertriglyceridemia
notes: Risk factor
- name: Hypercalcemia
notes: Risk factor
treatments:
- name: Pain Management
description: Analgesics, nerve blocks, endoscopic therapy.
evidence:
- reference: PMID:38680261
reference_title: "Pain management in chronic pancreatitis."
supports: SUPPORT
snippet: "Clinicians should follow a holistic approach to the management of CP-associated
pain, which must involve lifestyle changes that are coupled with analgesic medications
and other pain-relieving interventions."
explanation: Confirms that pain management in chronic pancreatitis requires
a multidisciplinary approach combining lifestyle changes with analgesic
medications.
- name: Pancreatic Enzyme Replacement
description: For exocrine insufficiency (lipase with meals).
evidence:
- reference: PMID:27941156
reference_title: "Efficacy of pancreatic enzyme replacement therapy in chronic pancreatitis: systematic review and meta-analysis."
supports: SUPPORT
snippet: "PERT improved CFA compared with baseline (83.7±6.0 vs 63.1±15.0, p<0.00001)"
explanation: Meta-analysis of 17 randomized controlled trials demonstrates
significant improvement in fat absorption with pancreatic enzyme
replacement therapy.
- reference: PMID:27941156
reference_title: "Efficacy of pancreatic enzyme replacement therapy in chronic pancreatitis: systematic review and meta-analysis."
supports: SUPPORT
snippet: "PERT improved coefficient of nitrogen absorption, reduced faecal fat
excretion, faecal nitrogen excretion, faecal weight and abdominal pain, without
significant adverse events."
explanation: PERT provides multiple benefits including improved nutrient
absorption, reduced steatorrhea, and pain reduction with a favorable
safety profile.
- name: Diabetes Management
description: Insulin often required for type 3c diabetes.
evidence:
- reference: PMID:28404095
reference_title: "Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer."
supports: PARTIAL
snippet: "The most commonly identified causes of type 3c diabetes are chronic
pancreatitis, pancreatic ductal adenocarcinoma, haemochromatosis, cystic fibrosis,
and previous pancreatic surgery."
explanation: Chronic pancreatitis is the most common cause of type 3c
diabetes, which requires specific management considerations including
insulin therapy.
- name: Nutritional Support
description: Small frequent meals, medium-chain triglycerides.
evidence:
- reference: PMID:30074926
reference_title: "Exocrine Pancreatic Insufficiency and Malnutrition in Chronic Pancreatitis: Identification, Treatment, and Consequences."
supports: SUPPORT
snippet: "There is a high prevalence of fat-soluble vitamin deficiencies, osteopathy,
and malnutrition in CP patients, which is underestimated due to a lack of effective
diagnosis and suboptimal therapies for EPI."
explanation: High prevalence of malnutrition and vitamin deficiencies in CP
patients underscores the importance of nutritional support as a treatment
component.
- name: Alcohol Cessation
description: Essential to slow progression.
evidence:
- reference: PMID:38013125
reference_title: "Impact of alcohol and smoking cessation on the course of chronic pancreatitis."
supports: SUPPORT
snippet: "Alcohol cessation in chronic pancreatitis reduces exocrine insufficiency,
abdominal pain, and local complications."
explanation: Large cohort study demonstrates that alcohol cessation reduces
key complications of chronic pancreatitis.
- reference: PMID:38013125
reference_title: "Impact of alcohol and smoking cessation on the course of chronic pancreatitis."
supports: SUPPORT
snippet: "Compared to patients with LTDH, 'former drinkers' had a lower rate of
exocrine insufficiency (29% vs. 59%) and pseudocysts (33% vs. 49%), were more
often relapse-free (37% vs. 5%), and had less abdominal pain."
explanation: Former drinkers show dramatically better outcomes including
lower exocrine insufficiency, fewer pseudocysts, and higher relapse-free
rates.
- name: Smoking Cessation
description: Reduces pain and slows progression.
evidence:
- reference: PMID:38013125
reference_title: "Impact of alcohol and smoking cessation on the course of chronic pancreatitis."
supports: PARTIAL
snippet: "The cumulative amount of nicotine consumed correlated with overall disease
severity and the development of pseudocysts."
explanation: Dose-dependent relationship between smoking and disease
severity supports smoking cessation as an important intervention.
- reference: PMID:15753536
reference_title: "Cigarette smoking accelerates progression of alcoholic chronic pancreatitis."
supports: SUPPORT
snippet: "Tobacco smoking increased significantly the risk of pancreatic calcifications
(hazard ratio (HR) 4.9 (95% confidence interval (CI) 2.3-10.5) for smokers v
non-smokers)"
explanation: The strong association between smoking and disease progression
(HR 4.9 for calcifications) supports the importance of smoking cessation.
- name: Endoscopic Therapy
description: Stricture dilation, stone removal, stenting.
evidence:
- reference: PMID:30654394
reference_title: "Endoscopic treatment of chronic pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Updated August 2018."
supports: SUPPORT
snippet: "ESGE suggests endoscopic therapy and/or extracorporeal shockwave lithotripsy
(ESWL) as the first-line therapy for painful uncomplicated chronic pancreatitis
(CP) with an obstructed main pancreatic duct (MPD) in the head/body of the pancreas."
explanation: European Society of Gastrointestinal Endoscopy guidelines
recommend endoscopic therapy as first-line treatment for painful chronic
pancreatitis with obstructed main pancreatic duct.
- name: Surgery
description: Drainage or resection procedures for refractory pain.
evidence:
- reference: PMID:18471517
reference_title: "Resection vs drainage in treatment of chronic pancreatitis: long-term results of a randomized trial."
supports: SUPPORT
snippet: "Both procedures provide adequate pain relief and quality of life after
long-term follow-up with no differences regarding exocrine and endocrine function."
explanation: Randomized trial with 7-year follow-up demonstrates that both
drainage and resection procedures provide adequate long-term pain relief
and quality of life.
classifications:
harrisons_chapter:
- classification_value: GASTROINTESTINAL
datasets:
references:
- reference: DOI:10.1002/cphy.c230008
title: 'Pancreatic Crosstalk in the Disease Setting: Understanding the Impact of
Exocrine Disease on Endocrine Function'
findings: []
- reference: DOI:10.1101/2024.10.30.620903
title: Chronic pancreatitis patient-derived organoids reveal new paths to
precision therapeutics
findings: []
- reference: DOI:10.3390/cancers15030761
title: 'Pancreatic Cancer in Chronic Pancreatitis: Pathogenesis and Diagnostic Approach'
findings: []
- reference: DOI:10.3390/gastroent15020022
title: The Pathogenesis of Pancreatitis and the Role of Autophagy
findings: []
- reference: DOI:10.69734/f83fbc79
title: 2. Diagnosis of Chronic Pancreatitis
findings: []
Pathophysiology description Chronic pancreatitis (CP) is a progressive fibroinflammatory disease of the exocrine pancreas characterized by recurrent acinar injury, ductal dysfunction, persistent immune activation, pancreatic stellate cell (PSC) activation, and extracellular matrix deposition leading to irreversible fibrosis, pain, and exocrine/endocrine insufficiency (steatorrhea and type 3c diabetes) (whitcomb20242.diagnosisof pages 1-3). Mechanistically, repeated acute pancreatitis (AP) episodes promote acinar damage, release of damage-associated molecular patterns (DAMPs; HMGB1, HSP70, ATP), and activation of pattern-recognition receptors such as TLR4, triggering NF-κB signaling, upregulation of NLRP3, and inflammasome assembly with caspase-1–dependent maturation of IL‑1β and IL‑18; ATP (via P2X7) and neutrophil extracellular trap–derived ROS further activate NLRP3, amplifying inflammation (tsomidis2024thepathogenesisof pages 13-15). Ductal bicarbonate secretion defects—often involving CFTR—impair luminal alkalinization, favor protein plugs and obstruction, and perpetuate injury (whitcomb20242.diagnosisof pages 3-4). Within the injured milieu, macrophage-derived cytokines (e.g., TGF‑β1) and other mediators activate PSCs, which deposit collagen I/III and fibronectin, driving desmoplasia; alcohol and tobacco can directly activate PSCs (villaca2024pancreaticcrosstalkin pages 12-14). Intracellular stress pathways contribute: ER stress, defective autophagy (e.g., LAMP-2 deficiency), mitochondrial dysfunction, and aberrant calcium signaling promote premature trypsinogen activation and acinar cell death, sustaining chronic inflammation (tsomidis2024thepathogenesisof pages 32-34, belfrageUnknownyearacademicdissertation pages 23-26). Neuro-immune remodeling (including TRPV1-positive sensory fibers and Schwann cells) contributes to chronic pain (belfrageUnknownyearacademicdissertation pages 23-26, cosquer2023pancreaticcancerin pages 2-3). Over years, CP increases pancreatic ductal adenocarcinoma (PDAC) risk via chronic inflammatory signaling (NF‑κB/STAT3), oxidative stress, and metaplastic programs (acinar-to-ductal metaplasia), with progression through PanIN lesions and canonical oncogenic changes (KRAS activation; TP53, CDKN2A, SMAD4 loss) (cosquer2023pancreaticcancerin pages 2-3).
Core Pathophysiology - Primary mechanisms: - Trypsin-dependent acinar injury: premature intrapancreatic trypsinogen activation with autodigestion and inflammation; genetic drivers include PRSS1 gain-of-function and reduced anti-trypsin activity from SPINK1/CTRC variants (osoriovasquez2024identificationofmolecular pages 15-18). - Ductal pathway dysfunction: impaired CFTR-mediated Cl−/HCO3− secretion reduces ductal pH/flow, fosters protein plugs and obstruction (whitcomb20242.diagnosisof pages 3-4). - Innate immune activation: DAMP→TLR4→NF‑κB drives NLRP3 inflammasome activation, IL‑1β/IL‑18 release, and recruitment of neutrophils/monocytes/macrophages (tsomidis2024thepathogenesisof pages 13-15). - PSC activation and fibrosis: TGF‑β autocrine and paracrine signaling converts quiescent PSCs to α‑SMA+ myofibroblast-like cells producing ECM (villaca2024pancreaticcrosstalkin pages 12-14). - Intracellular stress and organelle dysfunction: ER stress, defective autophagy, and mitochondrial dysfunction exacerbate acinar injury and inflammation (tsomidis2024thepathogenesisof pages 32-34). - Neuro-immune remodeling: TRPV1+ sensory nerves and Schwann cells participate in neurogenic inflammation and pain (cosquer2023pancreaticcancerin pages 2-3, belfrageUnknownyearacademicdissertation pages 23-26).
Oncogenic inflammation (NF‑κB/STAT3) and oxidative stress linking CP to PDAC risk (cosquer2023pancreaticcancerin pages 2-3).
Affected cellular processes:
Key Molecular Players - Genes/Proteins (HGNC): - PRSS1 (cationic trypsinogen): causal in hereditary CP via premature activation (osoriovasquez2024identificationofmolecular pages 15-18). - SPINK1 (trypsin inhibitor): risk allele reduces trypsin inhibition, increasing injury (osoriovasquez2024identificationofmolecular pages 15-18). - CFTR (chloride/bicarbonate channel): ductal dysfunction, reduced HCO3− secretion, obstruction (whitcomb20242.diagnosisof pages 3-4). - CTRC (chymotrypsin C): regulates trypsinogen activation; loss-of-function predisposes to CP (osoriovasquez2024identificationofmolecular pages 15-18). - CPA1 (carboxypeptidase A1): misfolding variants cause ER stress–mediated pancreatitis (osoriovasquez2024identificationofmolecular pages 15-18). - CLDN2 (claudin-2): tight junction risk locus linked to CP susceptibility and inflammatory milieu (whitcomb20242.diagnosisof pages 1-3, cosquer2023pancreaticcancerin pages 2-3). - CASR (calcium-sensing receptor): modulates pathological calcium signaling and trypsinogen activation (osoriovasquez2024identificationofmolecular pages 15-18).
Chemical entities (CHEBI): bicarbonate (ductal secretion) and reactive oxygen species (ROS) as inflammatory mediators in acinar injury (whitcomb20242.diagnosisof pages 3-4, tsomidis2024thepathogenesisof pages 13-15).
Cell types (CL): acinar cells (injury site), ductal epithelial cells (CFTR-mediated transport), PSCs (fibrosis), macrophages and T cells (immune regulation), Schwann cells/neurons (pain circuitry) (villaca2024pancreaticcrosstalkin pages 12-14, tsomidis2024thepathogenesisof pages 13-15, cosquer2023pancreaticcancerin pages 2-3).
Anatomical locations (UBERON): exocrine pancreas, pancreatic duct system (cosquer2023pancreaticcancerin pages 2-3, whitcomb20242.diagnosisof pages 3-4).
Biological Processes (for GO annotation) - Proteolysis/zymogen activation (GO:0006508) in acinar cells (PRSS1/CTRC) (osoriovasquez2024identificationofmolecular pages 15-18). - Anion/bicarbonate transport (GO:0006820) and regulation of exocrine pancreatic secretion (GO:0044060) in ducts (CFTR) (whitcomb20242.diagnosisof pages 3-4). - TGF‑β receptor signaling pathway (GO:0007179) driving PSC activation and ECM deposition (villaca2024pancreaticcrosstalkin pages 12-14). - Activation of NLRP3 inflammasome (GO:0072559) and cytokine-mediated signaling (IL‑1β/IL‑18) (tsomidis2024thepathogenesisof pages 13-15). - Response to oxidative stress (GO:0006979), ER stress, defective autophagy/lysosomal pathways, mitochondrial dysfunction (tsomidis2024thepathogenesisof pages 32-34). - Calcium ion homeostasis (GO:0055074) perturbations fueling trypsin activation (osoriovasquez2024identificationofmolecular pages 15-18).
Cellular Components - Zymogen granules (GO:0042588) in acinar cells (trypsinogen localization/activation) (osoriovasquez2024identificationofmolecular pages 15-18). - Endoplasmic reticulum (GO:0005783) and mitochondria (GO:0005739) as hubs of ER/mitochondrial stress (tsomidis2024thepathogenesisof pages 32-34). - Plasma membrane (GO:0005886) for CFTR and calcium/PRR signaling (whitcomb20242.diagnosisof pages 3-4, tsomidis2024thepathogenesisof pages 13-15). - Extracellular matrix (GO:0031012) deposition by PSCs (villaca2024pancreaticcrosstalkin pages 12-14).
Disease Progression (sequence of events) - Environmental/genetic triggers (alcohol, tobacco, gallstones; PRSS1/SPINK1/CFTR/CTRC/CPA1/CLDN2/CASR variants) initiate AP via acinar injury and zymogen activation (osoriovasquez2024identificationofmolecular pages 15-18, belfrageUnknownyearacademicdissertation pages 23-26). - AP events release DAMPs → TLR4/NF‑κB and NLRP3 inflammasome activation → IL‑1β/IL‑18 cytokine cascade, neutrophil/monocyte recruitment (tsomidis2024thepathogenesisof pages 13-15). - Ductal CFTR dysfunction reduces ductal bicarbonate/flow → protein plugs, intraductal hypertension and recurrent injury (whitcomb20242.diagnosisof pages 3-4). - Persistent inflammation activates PSCs via TGF‑β and other cytokines → ECM accumulation, fibrosis, ductal strictures (villaca2024pancreaticcrosstalkin pages 12-14). - Chronic fibrosis and neuronal remodeling produce persistent pain; progressive acinar loss causes exocrine insufficiency; islet involvement yields type 3c diabetes (whitcomb20242.diagnosisof pages 1-3, villaca2024pancreaticcrosstalkin pages 12-14). - Longstanding CP increases PDAC risk through chronic inflammatory/oxidative signaling (NF‑κB/STAT3) and precursor lesion evolution (PanIN), especially with tobacco exposure (cosquer2023pancreaticcancerin pages 2-3).
Phenotypic Manifestations (HPO) and links to mechanisms - Recurrent abdominal pain (HPO:0012531): neurogenic inflammation, TRPV1+ nerve remodeling; inflammatory mediators (cosquer2023pancreaticcancerin pages 2-3, belfrageUnknownyearacademicdissertation pages 23-26). - Exocrine pancreatic insufficiency (HPO:0001738) and steatorrhea (HPO:0002570): acinar loss; ductal obstruction (whitcomb20242.diagnosisof pages 1-3). - Diabetes mellitus due to pancreatic disease (type 3c) (HPO:0005978): islet involvement following exocrine injury (“exocrine–endocrine crosstalk”) (villaca2024pancreaticcrosstalkin pages 12-14). - Pancreatic duct stones/strictures (HPO:0025031): protein plugs and fibrosis related to ductal CFTR dysfunction and PSC-mediated remodeling (whitcomb20242.diagnosisof pages 3-4, villaca2024pancreaticcrosstalkin pages 12-14). - Increased risk of pancreatic cancer (HPO:0100626): chronic inflammatory milieu, KRAS/STAT3/NF‑κB pathways (cosquer2023pancreaticcancerin pages 2-3).
Expert opinions and analysis (authoritative sources) - Precision-medicine perspective emphasizes CP as an immune-mediated fibroinflammatory disorder with genetic subtypes (trypsin-dependent, protein-misfolding, ductal/CFTR, cellular injury/ER-response), underscoring need for early-stage biomarkers and genetic testing beyond PRSS1/SPINK1/CFTR/CTRC to include CLDN2 and other modifiers (whitcomb20242.diagnosisof pages 1-3). - Immune pathophysiology highlights TLR4–NLRP3 axis as central to progression from AP to CP with DAMP-driven cycles of inflammasome activation, supporting targeting of IL‑1β/IL‑18 and upstream signals (tsomidis2024thepathogenesisof pages 13-15). - PSC-centric fibrosis is maintained by TGF‑β autocrine loops and accounts for irreversible parenchymal remodeling; alcohol and tobacco directly activate PSCs, aligning with public health guidance for risk reduction (villaca2024pancreaticcrosstalkin pages 12-14).
Relevant statistics and data (recent) - CP is radiologically defined by chronic morphologic changes and functionally by exocrine/endocrine failure; major clinical unmet needs include diagnosing early CP and predicting progression (whitcomb20242.diagnosisof pages 1-3). - PDAC risk rises with long-standing CP; mechanistic links include chronic oxidative/inflammatory signaling and PanIN progression, with tobacco as an additional co-factor (cosquer2023pancreaticcancerin pages 2-3). Quantified risk varies by etiology (e.g., higher in hereditary forms), though precise pooled estimates were not provided in the retrieved excerpts and remain context-dependent.
Gene/protein annotations with ontology terms (examples) - PRSS1 (HGNC:9488): GO:0006508 proteolysis; GO:0042588 zymogen granule; Evidence: genetic causality in CP (osoriovasquez2024identificationofmolecular pages 15-18). - SPINK1 (HGNC:11244): GO:0006508 proteolysis; secreted inhibitor; Evidence: risk allele in CP (osoriovasquez2024identificationofmolecular pages 15-18). - CFTR (HGNC:1884): GO:0006820 anion transport; GO:0005886 plasma membrane; Evidence: ductal dysfunction in CP (whitcomb20242.diagnosisof pages 3-4). - CTRC (HGNC:2540): GO:0006508 proteolysis; Evidence: loss-of-function increases CP risk (osoriovasquez2024identificationofmolecular pages 15-18). - CPA1 (HGNC:2293): GO:0005783 ER; misfolding/ER stress pathway (osoriovasquez2024identificationofmolecular pages 15-18). - CLDN2 (HGNC:2045): tight junction; inflammatory susceptibility (whitcomb20242.diagnosisof pages 1-3, cosquer2023pancreaticcancerin pages 2-3). - CASR (HGNC:1514): GO:0055074 calcium ion homeostasis; Evidence: trypsin activation context (osoriovasquez2024identificationofmolecular pages 15-18).
Cell type involvement (CL terms) - Pancreatic stellate cell (CL:0000632): PSC activation → ECM fibrosis (villaca2024pancreaticcrosstalkin pages 12-14). - Macrophage (CL:0000235): NLRP3 activation, cytokine production (tsomidis2024thepathogenesisof pages 13-15). - T cell (CL:0000084): adaptive modulation, potential Th17/Treg balance (villaca2024pancreaticcrosstalkin pages 12-14). - Schwann cell/Neuron (CL:0002573/CL:0000540): neurogenic inflammation and pain (cosquer2023pancreaticcancerin pages 2-3).
Anatomical locations (UBERON terms) - Pancreas (UBERON:0001264); Exocrine pancreas (UBERON:0001044); Pancreatic duct (UBERON:0008970) (cosquer2023pancreaticcancerin pages 2-3, whitcomb20242.diagnosisof pages 3-4).
Chemical entities (CHEBI terms) - Bicarbonate (CHEBI:17544) and ROS (CHEBI:26523) in ductal transport and oxidative injury (whitcomb20242.diagnosisof pages 3-4, tsomidis2024thepathogenesisof pages 13-15).
Evidence items and URLs (selected with quotes) - DAMP–TLR4–NLRP3/IL‑1β axis (tsomidis2024thepathogenesisof pages 13-15): “DAMPs (HMGB1, HSP70, ATP) activate NF‑κB via TLR4 and upregulate NLRP3 … resulting in IL‑1β/IL‑18 maturation and secretion.” 2024; https://doi.org/10.3390/gastroent15020022. - PSC activation/fibrosis (villaca2024pancreaticcrosstalkin pages 12-14): “Active PSCs express TGFβ, promoting autocrine inhibition of collagen degradation and fibrosis.” 2024; https://doi.org/10.1002/cphy.c230008. - Autophagy defects (tsomidis2024thepathogenesisof pages 32-34): “Impaired autophagy induces chronic atrophic pancreatitis.” 2024; https://doi.org/10.3390/gastroent15020022. - Ductal CFTR dysfunction (whitcomb20242.diagnosisof pages 3-4): genetic framework and ductal physiology; 2024; https://doi.org/10.69734/f83fbc79. - Genetic risk (osoriovasquez2024identificationofmolecular pages 15-18): PRSS1, SPINK1, CFTR, CTRC, CPA1 highlighted in CP genetics; 2024 preprint; https://doi.org/10.1101/2024.10.30.620903. - CP→PDAC links (cosquer2023pancreaticcancerin pages 2-3): “Mechanisms implicated include oxidative stress … activation of NF‑κB and STAT3 pathways.” 2023; https://doi.org/10.3390/cancers15030761.
Structured artifacts |Entity type|Name (ontology ID / HGNC / CHEBI / CL / UBERON)|Role in CP pathophysiology (1–2 sentences)|Pathway / GO BP terms (selected)|Cellular component (GO CC terms)|Evidence (year; URL)|Citation ID| |---|---|---|---|---|---|---| |Gene|PRSS1 (HGNC:PRSS1)|Encodes cationic trypsinogen; gain‑of‑function PRSS1 variants cause premature intrapancreatic trypsin activation driving acinar autodigestion and recurrent injury.|Proteolysis (GO:0006508)|Zymogen granule (GO:0042588)|2024; https://doi.org/10.1101/2024.10.30.620903|(osoriovasquez2024identificationofmolecular pages 15-18)| |Gene|SPINK1 (HGNC:SPINK1)|Secreted trypsin inhibitor; loss or reduced function lowers protection against intrapancreatic trypsin activity and increases CP risk.|Proteolysis (GO:0006508)|Zymogen granule / secreted (GO:0042588)|2024; https://doi.org/10.1101/2024.10.30.620903|(osoriovasquez2024identificationofmolecular pages 15-18)| |Gene|CFTR (HGNC:CFTR)|Apical chloride/bicarbonate channel in ductal epithelium; CFTR dysfunction reduces ductal bicarbonate/fluid secretion, promoting protein plugs and obstructive injury.|Anion transport (GO:0006820); regulation of exocrine pancreatic secretion (GO:0044060)|Plasma membrane (GO:0005886)|2024; https://doi.org/10.69734/f83fbc79|(whitcomb20242.diagnosisof pages 3-4)| |Gene|CTRC (HGNC:CTRC)|Chymotrypsin C degrades active trypsin and regulates trypsinogen activation; CTRC loss‑of‑function variants reduce trypsin degradation and predispose to CP.|Proteolysis (GO:0006508)|Zymogen granule (GO:0042588)|2024; https://doi.org/10.1101/2024.10.30.620903|(osoriovasquez2024identificationofmolecular pages 15-18)| |Gene|CPA1 (HGNC:CPA1)|Carboxypeptidase A1; certain misfolding variants cause ER stress and acinar cell injury leading to CP (protein‑misfolding pathway).|Proteolysis (GO:0006508); response to ER stress (related to GO:0006979)|Endoplasmic reticulum (GO:0005783)|2024; https://doi.org/10.1101/2024.10.30.620903|(osoriovasquez2024identificationofmolecular pages 15-18)| |Gene|CLDN2 (HGNC:CLDN2)|Claudin‑2, a tight junction protein in ducts; risk variants alter ductal barrier/ion permeability and are associated with increased CP susceptibility and inflammation.|Regulation of exocrine pancreatic secretion (GO:0044060); calcium ion homeostasis (GO:0055074)|Plasma membrane / tight junction (GO:0005886)|2023; https://doi.org/10.3390/cancers15030761|(cosquer2023pancreaticcancerin pages 2-3)| |Gene|CASR (HGNC:CASR)|Calcium‑sensing receptor expressed in pancreatic cells; modulates calcium signaling that can influence trypsinogen activation and acinar injury.|Calcium ion homeostasis (GO:0055074)|Plasma membrane (GO:0005886)|2024; https://doi.org/10.1101/2024.10.30.620903|(osoriovasquez2024identificationofmolecular pages 15-18)| |Cell type (CL)|Pancreatic stellate cell (CL:0000632)|Quiescent PSCs activate after injury to secrete ECM (collagens, fibronectin) and α‑SMA, driving desmoplasia and progressive pancreatic fibrosis.|TGF‑beta receptor signaling pathway (GO:0007179)|Extracellular matrix (GO:0031012)|2024; https://doi.org/10.1002/cphy.c230008|(villaca2024pancreaticcrosstalkin pages 12-14)| |Cell type (CL)|Macrophage (CL:0000235)|Infiltrating and resident macrophages produce IL‑1β/IL‑6/TNF and activate inflammasomes (NLRP3), amplifying inflammation and promoting PSC activation and fibrosis.|Activation of NLRP3 inflammasome (GO:0072559); response to oxidative stress (GO:0006979)|Mitochondrion / cytosol (ROS and inflammasome signaling) (GO:0005739)|2024; https://doi.org/10.3390/gastroent15020022|(tsomidis2024thepathogenesisof pages 13-15)| |Cell type (CL)|T cell (CL:0000084)|Adaptive immune cells (e.g., Th17, regulatory T cells) modulate chronic inflammation in CP and can shape macrophage/PSC responses and disease severity.|Response to oxidative stress (GO:0006979); cytokine‑mediated signaling (related pathways)|Plasma membrane / immunological synapse (GO:0005886)|2024; https://doi.org/10.1002/cphy.c230008|(villaca2024pancreaticcrosstalkin pages 12-14)| |Cell type (CL)|Schwann cell / Neuron (CL:0002573 / CL:0000540)|Peripheral nerves and Schwann cells undergo remodeling (TRPV1‑mediated neurogenic inflammation), driving neurogenic pain and neuro‑immune crosstalk in CP.|Calcium ion homeostasis (GO:0055074); neurogenic inflammation (related pathways)|Plasma membrane / synapse (GO:0005886)|2023; https://doi.org/10.3390/cancers15030761|(cosquer2023pancreaticcancerin pages 2-3)| |Anatomical (UBERON)|Pancreas (UBERON:0001264)|Organ‑level site of exocrine (acinar/ductal) injury in CP; progressive acinar loss, ductal changes and fibrosis lead to exocrine/endocrine insufficiency.|Regulation of exocrine pancreatic secretion (GO:0044060)|Zymogen granule / secretory compartments (GO:0042588)|2023; https://doi.org/10.3390/cancers15030761|(cosquer2023pancreaticcancerin pages 2-3)| |Anatomical (UBERON)|Pancreatic duct (UBERON:0008970)|Ductal epithelium where CFTR‑dependent bicarbonate secretion maintains lumenal pH; duct dysfunction predisposes to protein plug formation and obstruction.|Anion transport (GO:0006820)|Plasma membrane (GO:0005886)|2024; https://doi.org/10.69734/f83fbc79|(whitcomb20242.diagnosisof pages 3-4)| |Chemical (CHEBI)|Bicarbonate (CHEBI:17544)|Secreted by ductal cells via CFTR/SLC26A9 to alkalinize lumen; reduced bicarbonate favors mucoprotein aggregation and ductal obstruction in CP.|Anion transport (GO:0006820)|Extracellular / lumenal space; associated with apical transporters (GO:0005886)|2024; https://doi.org/10.69734/f83fbc79|(whitcomb20242.diagnosisof pages 3-4)|
Table: Compact table mapping key genes, cells, anatomical sites and a chemical relevant to chronic pancreatitis to ontology identifiers, concise roles, representative GO biological processes and cellular components, and supporting 2023–2024 evidence (with source URLs). This can be used to populate ontology‑annotated knowledge bases and support curated mechanistic claims.
"DAMPs (HMGB1, HSP70, ATP) activate NF-κB via TLR4 and upregulate NLRP3, promoting assembly of the NLRP3 inflammasome with ASC and pro-caspase-1; ATP (via P2X7) and ROS (including NET-derived ROS) activate NLRP3/caspase-1, resulting in IL-1β/IL-18 maturation and secretion." — 2024; https://doi.org/10.3390/gastroent15020022 (tsomidis2024thepathogenesisof pages 13-15)
"Active PSCs express TGFβ, promoting autocrine inhibition of collagen degradation and fibrosis." — 2024; https://doi.org/10.1002/cphy.c230008 (villaca2024pancreaticcrosstalkin pages 12-14)
"PSCs produce ECM (collagen I/III, fibronectin) leading to fibrosis." — 2024; https://doi.org/10.1002/cphy.c230008 (villaca2024pancreaticcrosstalkin pages 12-14)
"Impaired autophagy induces chronic atrophic pancreatitis." — 2024; https://doi.org/10.3390/gastroent15020022 (tsomidis2024thepathogenesisof pages 32-34)
"we identified a high prevalence of ductal CFTR dysfunction, which could be restored using a combination of CFTR correctors and potentiators." — 2024; https://doi.org/10.1101/2024.10.30.620903 (osoriovasquez2024identificationofmolecular pages 15-18)
"pancreatitis susceptibility genes commonly tested ("PRSS1, CFTR, SPINK1 and CTRC")" — 2024; https://doi.org/10.69734/f83fbc79 (whitcomb20242.diagnosisof pages 3-4)
"Mechanisms implicated include oxidative stress, COX2-driven inflammation, and activation of NF-κB and STAT3 pathways." — 2023; https://doi.org/10.3390/cancers15030761 (cosquer2023pancreaticcancerin pages 2-3)
Blockquote: Selected verbatim quotes from 2023–2024 sources that support core chronic pancreatitis mechanisms (innate immune inflammasome activation, PSC/TGF‑β fibrosis, autophagy defects, CFTR/ductal dysfunction, genetic risk, and links to oncogenic inflammation). These provide citable evidence snippets for knowledge‑base entries.
Limitations and gaps - While multiple recent sources substantiate genetic and immuno‑fibrotic mechanisms, precise global incidence/prevalence of CP and pooled PDAC risk estimates could not be extracted from the retrieved excerpts and should be supplemented from epidemiologic syntheses for 2023–2024 where available.
References (by citation IDs with URLs) - pqac-00000004: Whitcomb & Yadav. 2. Diagnosis of Chronic Pancreatitis. 2024. https://doi.org/10.69734/f83fbc79. - pqac-00000000: Tsomidis et al. The pathogenesis of pancreatitis and the role of autophagy. 2024. https://doi.org/10.3390/gastroent15020022. - pqac-00000007: Villaca & Mastracci. Pancreatic Crosstalk… 2024. https://doi.org/10.1002/cphy.c230008. - pqac-00000005: Tsomidis et al. (additional sections on autophagy/NETs). 2024. https://doi.org/10.3390/gastroent15020022. - pqac-00000003: Whitcomb & Yadav. Genetics/ductal physiology. 2024. https://doi.org/10.69734/f83fbc79. - pqac-00000006: Osorio‑Vasquez et al. CP organoids/genetics (preprint). 2024. https://doi.org/10.1101/2024.10.30.620903. - pqac-00000002: Le Cosquer et al. Pancreatic Cancer in Chronic Pancreatitis. 2023. https://doi.org/10.3390/cancers15030761.
References
(whitcomb20242.diagnosisof pages 1-3): David Whitcomb and Dhiraj Yadav. 2. diagnosis of chronic pancreatitis. SMART-MD Journal of Precision Medicine, 1:4-13, Jul 2024. URL: https://doi.org/10.69734/f83fbc79, doi:10.69734/f83fbc79. This article has 0 citations.
(tsomidis2024thepathogenesisof pages 13-15): Ioannis Tsomidis, A. Voumvouraki, and E. Kouroumalis. The pathogenesis of pancreatitis and the role of autophagy. Gastroenterology Insights, Apr 2024. URL: https://doi.org/10.3390/gastroent15020022, doi:10.3390/gastroent15020022. This article has 10 citations.
(whitcomb20242.diagnosisof pages 3-4): David Whitcomb and Dhiraj Yadav. 2. diagnosis of chronic pancreatitis. SMART-MD Journal of Precision Medicine, 1:4-13, Jul 2024. URL: https://doi.org/10.69734/f83fbc79, doi:10.69734/f83fbc79. This article has 0 citations.
(villaca2024pancreaticcrosstalkin pages 12-14): Catharina B.P. Villaca and Teresa L. Mastracci. Pancreatic crosstalk in the disease setting: understanding the impact of exocrine disease on endocrine function. Comprehensive Physiology, 14 2:5371-5387, Mar 2024. URL: https://doi.org/10.1002/cphy.c230008, doi:10.1002/cphy.c230008. This article has 3 citations and is from a peer-reviewed journal.
(tsomidis2024thepathogenesisof pages 32-34): Ioannis Tsomidis, A. Voumvouraki, and E. Kouroumalis. The pathogenesis of pancreatitis and the role of autophagy. Gastroenterology Insights, Apr 2024. URL: https://doi.org/10.3390/gastroent15020022, doi:10.3390/gastroent15020022. This article has 10 citations.
(belfrageUnknownyearacademicdissertation pages 23-26): H Belfrage. Academic dissertation. Unknown journal, Unknown year.
(cosquer2023pancreaticcancerin pages 2-3): Guillaume Le Cosquer, Charlotte Maulat, Barbara Bournet, Pierre Cordelier, Etienne Buscail, and Louis Buscail. Pancreatic cancer in chronic pancreatitis: pathogenesis and diagnostic approach. Cancers, 15:761, Jan 2023. URL: https://doi.org/10.3390/cancers15030761, doi:10.3390/cancers15030761. This article has 65 citations and is from a poor quality or predatory journal.
(osoriovasquez2024identificationofmolecular pages 15-18): Victoria Osorio-Vasquez, Jan C. Lumibao, Kristina L. Peck, Kathryn Lande, Jonathan Zhu, McKenna Stamp, Shira R. Okhovat, Hyemin Song, Satoshi Ogawa, Jasper Hsu, Yang Dai, Angelica Rock, Chelsea Bottomley, Ethan Thomas, Alexandra Fowler, T’Onj McGriff, Siri Larsen, Muhamad Abdulla, Phil Greer, Jessica Gibson, Michael Downes, Ronald Evans, Jingjing Zou, Andrew M. Lowy, David C. Whitcomb, Rebekah White, Melena Bellin, Herve Tiriac, and Dannielle D. Engle. Identification of molecular and functional subtypes using chronic pancreatitis patient-derived organoid models. bioRxiv, Nov 2024. URL: https://doi.org/10.1101/2024.10.30.620903, doi:10.1101/2024.10.30.620903. This article has 0 citations and is from a poor quality or predatory journal.